desember 2021: CAR T-Cell therapy is currently approved for some forms of leukemia, lymphoma, and multiple myeloma. Researchers have now also developed the corresponding GD2 CAR T-cell therapy for the treatment of neuroblastoma, i.e., childhood brain tumors. Lung cancer, stomach cancer, liver cancer, breast cancer, and other adult cancers have the highest incidence. When discussing children’s cancer, many people instinctively believe that it is identical to adult cancer.
However, whether it is the cause of cancer or the type of cancer, there is a significant difference between childhood cancer and adult cancer. The most frequent childhood tumour is taugaæxli, which is more common than lung cancer, gastric cancer, and other cancers. Neuroblastoma can account for half of all cancers in children under the age of five, greatly exceeding the proportion of various malignancies in adult cancers.
Hins vegar er 5 ára lifun sjúklinga með taugablöðruæxli enn ekki sérstaklega mikil og nærri 40% til 50% sjúklinga geta enn ekki náð langtíma lækningu. Á sama hátt, ef æxlið kemur aftur, er barnið enn í hættu, svipað og gerist þegar fullorðinskrabbamein kemur aftur.
Is there a new treatment available?
CAR-T frumumeðferð has opened up a whole new universe in the field of advanced relapse and refractory B-cell cancers in recent years, and it has also allowed people to witness how effective it can be.
As a result, researchers have created a GD2-CAR-T cell therapy for the treatment of neuroblastoma for the matching target of neuroblastoma. The findings of the clinical study were published in the most recent issue of “Science Translational Medicine.”
Þessi rannsókn náði til alls 12 börnum með bakslag/óþolandi taugafrumuæxli. Á heildina litið þolaðist lyfið vel og engin áhrif utan markhópsins sáust. Þrátt fyrir þá staðreynd að það hafi ekki náð hlutlægri klínískri svörun, tóku vísindamenn eftir raunverulegum lækningalegum ávinningi hjá sumum einstaklingum.
Sjúklingur 25/010 er 8 ára stúlka með umfangsmikil meinvörp í taugablöðruæxlum, þar á meðal umtalsverð beinmeinvörp (endurkoma eftir fjórðu meðferð). Almennt ástand hefur batnað verulega eftir 28 daga CAR-T frumumeðferð, og æxlisvefurinn hefur einnig sýnt útbreitt æxlisdrep.
Patient 25/013 is a 10-year-old girl who has had five treatments for multiple recurrent localised neuroblastomas. There were tumour nodules in the neck before therapy, but no distant metastases. An MRI showed that the tumour had shrunk after treatment. Following a tumour biopsy, it was discovered that the tumour had significant necrosis.
Sjúklingur 25/018 er 10 ára gamalt barn sem er með endurtekið taugafrumuæxli sem hefur breiðst út um líkamann. Hann átti þrjár lotur fyrir og eftir, og vandamál hans voru létt vegna meðferðanna.
However, while this study has demonstrated that the treatment is effective, after experiencing the peak of CAR-T cell therapy, the long-term expansion of CAR-T cells is not visible, making the treatment effect ineffective. It finally resulted in tumour recurrence, however, before that, this therapy helped 013 and 018 live for approximately 5 months longer.
Although this new CAR-T cell therapy cannot match the efficacy and durability of CD19-CAR-T cell therapy in haematological cancers, it demonstrates that CAR-T cell therapy can still be employed in the entity once a suitable target is identified. In the treatment of tumours, it has potent anti-tumor effects. To improve its therapeutic efficacy in solid malignancies, researchers will combine CAR-T activation with immune checkpoint drugs (PD-1 inhibitors).
The safety of this solid tumour CAR-T cell treatment is currently assured. The patient got CRS as a result of the medication, although no major neurotoxic reactions occurred. Medical teams receiving CAR-T cell therapy may soon have to respond to CRS as a matter of course. CAR-T cell therapy still has a long way to go in terms of overcoming solid tumours, but it will get there someday.
